LENZ Therapeutics

# LENZ Therapeutics: Correcting the Record

LENZ Therapeutics is not a technology company—it is a pharmaceutical company focused on commercializing an FDA-approved ophthalmic drug product.[2][3]

High-Level Overview

LENZ Therapeutics is a late-stage clinical pharmaceutical company developing innovative eye care solutions.[1] The company's core mission centers on commercializing VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for treating presbyopia—the age-related loss of near vision.[2][3]

The company addresses a massive market opportunity: presbyopia impacts an estimated 1.8 billion people globally and 128 million people in the United States.[3] Adults over 50 lose on average 1.5 lines of near vision per 6 years, creating sustained demand for pharmaceutical solutions that restore near vision and reduce dependence on reading glasses.[2] LENZ is commercializing VIZZ™ in the United States while establishing international licensing partnerships to expand global access.[2]

Origin Story

LENZ Therapeutics was founded in 2013 and is headquartered in San Diego, California (with offices in Solana Beach).[1][4] The company is led by Evert Schimmelpennink, President and CEO, who brings a proven track record in building and scaling biopharmaceutical companies and securing funding around compelling strategies.[2]

The company has secured substantial venture capital backing, with funding in the $100-500 million range, supported by multiple blue-chip venture capital investors.[1] This capital has enabled LENZ to advance its lead program through clinical development and ultimately achieve FDA approval for VIZZ™—a significant milestone demonstrating the viability of the aceclidine-based approach to presbyopia treatment.

Core Differentiators

• First-mover advantage: VIZZ™ is the first and only FDA-approved aceclidine-based eye drop for presbyopia, establishing a novel pharmaceutical category.[2][3]

• Massive addressable market: With 128 million Americans and 1.8 billion people globally affected by presbyopia, the potential patient population is substantially larger than most specialty pharmaceutical markets.[3]

• Experienced leadership: The executive team and board include seasoned pharmaceutical executives with track records in commercialization, regulatory success, and scaling operations.[2][5]

• Commercial infrastructure: LENZ is actively building a specialty sales organization, with multiple open positions for sales representatives and district managers across U.S. regions, indicating active market preparation.[1]

Role in the Broader Healthcare Landscape

LENZ operates within the broader trend of precision ophthalmology and age-related disease treatment. As global populations age, presbyopia represents an underserved condition affecting nearly every adult over 50. The shift toward pharmaceutical solutions (rather than purely optical corrections like reading glasses) reflects evolving patient preferences for convenience and freedom from corrective devices.

The company's focus on a large, well-defined patient population with a clear unmet need positions it within the growing specialty pharmaceutical sector targeting age-related conditions. Success with VIZZ™ could validate the aceclidine mechanism for ophthalmology and potentially open doors to additional indications or formulations.

Quick Take & Future Outlook

LENZ Therapeutics stands at an inflection point: having achieved FDA approval for VIZZ™, the company is transitioning from clinical development to commercial execution. The near-term focus will be on market penetration in the United States, establishing reimbursement pathways, and building physician and patient awareness of this novel treatment option.

The company's international licensing strategy suggests ambitions to become a global player in presbyopia treatment. Success will depend on clinical adoption rates, pricing strategy, and competitive responses from larger pharmaceutical companies that may enter the presbyopia market. For investors, LENZ represents a bet on both the aceclidine mechanism and the broader thesis that large, aging populations will drive demand for pharmaceutical solutions to age-related vision loss.